quinazolines has been researched along with diethylnitrosamine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barbu, V; Cacheux, W; Clergue, F; Desbois-Mouthon, C; Housset, C; Poupon, R; Rey, C; Rosmorduc, O; Schiffer, E; Wendum, D | 1 |
| Bardeesy, N; Caravan, P; Chen, X; Crenshaw, A; DePeralta, DK; Fuchs, BC; Fujii, T; Golub, TR; Gupta, S; Hoshida, Y; Kuroda, T; Lanuti, M; Lauwers, GY; McGinn, CM; Onofrio, R; Schmitt, AD; Tanabe, KK; Taylor, B; Wei, L; Winckler, W; Yamada, S | 1 |
2 other study(ies) available for quinazolines and diethylnitrosamine
| Article | Year |
|---|---|
Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Diethylnitrosamine; ErbB Receptors; Gefitinib; Liver Cirrhosis; Liver Neoplasms; Male; Quinazolines; Rats; Rats, Wistar; Signal Transduction; Transforming Growth Factor alpha | 2005 |
Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma.
Topics: Animals; Bile Ducts; Carbon Tetrachloride; Carcinoma, Hepatocellular; Cell Proliferation; Cells, Cultured; Diethylnitrosamine; Disease Models, Animal; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Hepatic Stellate Cells; Hepatocytes; Humans; Ligation; Liver Cirrhosis; Liver Neoplasms; Male; Mice; Mice, Inbred Strains; Phosphorylation; Prognosis; Quinazolines; Rats; Rats, Wistar; Transcriptome | 2014 |